|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neoptolemos JP, Kleeff J, Michl P,
Costello E, Greenhalf W and Palmer DH: Therapeutic developments in
pancreatic cancer: Current and future perspectives. Nat Rev
Gastroenterol Hepatol. 15:333–348. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsuchida H, Fujii T, Mizuma M, Satoi S,
Igarashi H, Eguchi H, Kuroki T, Shimizu Y, Tani M, Tanno S, et al:
Prognostic importance of peritoneal washing cytology in patients
with otherwise resectable pancreatic ductal adenocarcinoma who
underwent pancreatectomy: A nationwide, cancer registry-based study
from the Japan pancreas society. Surgery. 166:997–1003. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanaka M, Mihaljevic AL, Probst P, Heckler
M, Klaiber U, Heger U, Büchler MW and Hackert T: Meta-analysis of
recurrence pattern after resection for pancreatic cancer. Br J
Surg. 106:1590–1601. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Satoi S, Murakami Y, Motoi F, Uemura K,
Kawai M, Kurata M, Sho M, Matsumoto I, Yanagimoto H, Yamamoto T, et
al: Reappraisal of peritoneal washing cytology in 984 patients with
pancreatic ductal adenocarcinoma who underwent margin-negative
resection. J Gastrointest Surg. 19:6–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakano Y, Kitago M, Matsuda S, Nakamura Y,
Fujita Y, Imai S, Shinoda M, Yagi H, Abe Y, Hibi T, et al: KRAS
mutations in cell-free DNA from preoperative and postoperative sera
as a pancreatic cancer marker: a retrospective study. Br J Cancer.
118:662–669. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yokose T, Kitago M, Matsuda S, Sasaki Y,
Masugi Y, Nakamura Y, Shinoda M, Yagi H, Abe Y, Oshima G, et al:
Combination of KRAS and SMAD4 mutations in formalin-fixed
paraffin-embedded tissues as a biomarker for pancreatic cancer.
Cancer Sci. 111:2174–2182. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sugimori M, Sugimori K, Tsuchiya H, Suzuki
Y, Tsuyuki S, Kaneta Y, Hirotani A, Sanga K, Tozuka Y, Komiyama S,
et al: Quantitative monitoring of circulating tumor DNA in patients
with advanced pancreatic cancer undergoing chemotherapy. Cancer
Sci. 111:266–278. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nagai M, Sho M, Akahori T, Nakagawa K and
Nakamura K: Application of liquid biopsy for surgical management of
pancreatic cancer. Ann Gastroenterol Surg. 4:216–223. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldman D and Domschke K: Making sense of
deep sequencing. Int J Neuropsychopharmacol. 17:1717–1725. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deveson IW, Gong B, Lai K, LoCoco JS,
Richmond TA, Schageman J, Zhang Z, Novoradovskaya N, Willey JC,
Jones W, et al: Evaluating the analytical validity of circulating
tumor DNA sequencing assays for precision oncology. Nat Biotechnol.
39:1115–1128. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Patel A, Hissong E, Rosado L, Burkhardt R,
Cong L, Alperstein SA, Siddiqui MT, Parl HJ, Song W, Velu PD, et
al: Next-generation sequencing of cell-free DNA extracted from
pleural effusion supernatant: Applications and challenges. Front
Med (Lausanne). 8:6623122021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiba K, Hata T, Mizuma M, Matsuda K, Aoki
S, Takadate T, Kawaguchi K, Nakagawa K, Morikawa T, Motoi F, et al:
Impact of tumor-derived DNA testing in peritoneal lavage of
pancreatic cancer patients with and without occult intra-abdominal
metastases. Ann Surg Oncol. 29:2685–2697. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang SR, Mooney KL, Libiran P, Jones CD,
Joshi R, Lau HD, Stehr H, Berry GJ, Zehnder JL, Long SR, et al:
Targeted deep sequencing of cell-free DNA in serous body cavity
fluids with malignant, suspicious, and benign cytology. Cancer
Cytopathol. 128:43–56. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bae GE, Kim SH, Choi MK, Kim JM and Yeo
MK: Targeted sequencing of ascites and peritoneal washing fluid of
patients with gastrointestinal cancers and their clinical
applications and limitations. Front Oncol. 11:7127542021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mayo-de-Las-Casas C, Velasco A, Sanchez D,
Martínez-Bueno A, Garzón-Ibáñez M, Gatius S, Ruiz-Miró M,
Gonzalez-Tallada X, Llordella I, Tresserra F, et al: Detection of
somatic mutations in peritoneal lavages and plasma of endometrial
cancer patients: A proof-of-concept study. Int J Cancer.
147:277–284. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Compton CC and Henson DE: Protocol for the
examination of specimens removed from patients with carcinoma of
the exocrine pancreas: A basis for checklists. Cancer committee,
college of American pathologists. Arch Pathol Lab Med.
121:1129–1136. 1997.PubMed/NCBI
|
|
19
|
Nakamura K, Aimono E, Tanishima S, Imai M,
Nagatsuma AK, Hayashi H, Yoshimura Y, Nakayama K, Kyo S and
Nishihara Hl: Intratumoral genomic heterogeneity may hinder
precision medicine strategies in patients with serous ovarian
carcinoma. Diagnostics (Basel). 10:2002020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tsumura K, Arai E, Tian Y, Shibuya A,
Nishihara H, Yotani T, Yamada Y, Takahashi Y, Maeshima AM, Fujimoto
H, et al: Establishment of permutation for cancer risk estimation
in the urothelium based on genome-wide DNA methylation analysis.
Carcinogenesis. 40:1308–1319. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shin SH, Kim SC, Hong SM, Kim YH, Song KB,
Park KM and Lee YJ: Genetic alterations of K-ras, p53, c-erbB-2,
and DPC4 in pancreatic ductal adenocarcinoma and their correlation
with patient survival. Pancreas. 42:216–222. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schlitter AM, Segler A, Steiger K,
Michalski CW, Jäger C, Konukiewitz B, Pfarr N, Endris V,
Bettstetter M, Kong B, et al: Molecular, morphological and survival
analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs):
Identification of prognostic subtypes. Sci Rep. 7:410642017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Olmedillas-López S, García-Arranz M and
García-Olmo D: Current and emerging applications of droplet digital
PCR in oncology. Mol Diagn Ther. 21:493–510. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huerta M, Roselló S, Sabater L, Ferrer A,
Tarazona N, Roda D, Gambardella V, Alfaro-Cervelló C, Garcés-Albir
M, Cervantes A and Ibarrola-Villava M: Circulating tumor DNA
detection by digital-droplet PCR in pancreatic ductal
adenocarcinoma: A systematic review. Cancers (Basel). 13:9942021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamada S, Fujii T, Yamamoto T, Takami H,
Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S, et
al: Phase I/II study of adding intraperitoneal paclitaxel in
patients with pancreatic cancer and peritoneal metastasis. Br J
Surg. 107:1811–1817. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kilgour E, Rothwell DG, Brady G and Dive
C: Liquid biopsy-based biomarkers of treatment response and
resistance. Cancer Cell. 37:485–495. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Conroy T, Hammel P, Hebbar M, Ben
Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi
JJ, et al: FOLFIRINOX or gemcitabine as adjuvant therapy for
pancreatic cancer. N Engl J Med. 379:2395–2406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ueno M, Morinaga S, Hashimoto Y, Umemoto
K, Sasahira N, Saiura A, Seyama Y, Honda G, Ioka T, Takahashi H, et
al: Tolerability of nab-paclitaxel plus gemcitabine as adjuvant
setting in Japanese patients with resected pancreatic cancer: Phase
I study. Pancreas. 50:83–88. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Samorodnitsky E, Jewell BM, Hagopian R,
Miya J, Wing MR, Lyon E, Damodaran S, Bhatt D, Reeser JW, Datta J
and Roychowdhury S: Evaluation of hybridization capture versus
amplicon-based methods for whole-exome sequencing. Hum Mutat.
36:903–914. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hashimoto D, Arima K, Yokoyama N,
Chikamoto A, Taki K, Inoue R, Kaida T, Higashi T, Nitta H, Ohmuraya
M, et al: Heterogeneity of KRAS mutations in pancreatic ductal
adenocarcinoma. Pancreas. 45:1111–1114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baldus SE, Schaefer KL, Engers R, Hartleb
D, Stoecklein NH and Gabbert HE: Prevalence and heterogeneity of
KRAS, BRAF, and PIK3CA mutations in primary colorectal
adenocarcinomas and their corresponding metastases. Clin Cancer
Res. 16:790–799. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
